Biocon receives EIR for its Bommansandra facility
The inspection was carried out from January 20-24, 2020
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
EIR
Dr Reddy’s gets EIR from USFDA for Srikakulam plant
All facilities under warning letter are now determined as ‘voluntary action indicated’
Natco Pharma gets EIR from USFDA for Telangana facility
USFDA had conducted pre-approval inspection at Natco’s facility in Kothur village from March 2-6, 2020
Biocon Biologics gets EIR from US FDA for two manufacturing facilities
The formal closure of the US FDA inspection is expected to enable filing of marketing authorisation applications for the company's…
Lupin’s Nagpur Facility Receives EIR from US FDA
The inspection for the facility was carried out by the US FDA between January 6, 2020 and January 10, 2020
Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from US FDA
The Inspection has been closed with a “VAI” (Voluntary Action Indicated) classification in the EIR, for the three observations…
Alembic Pharma gets EIR from US FDA for Karakhadi API facility
The company has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the…
Marksans Pharma gets EIR from US FDA for New York unit
In a regulatory filing, the company announced "receipt of the EIR from US Food and Drug Administration (US FDA) in respect of…
Cadila Healthcare gets EIR from US FDA for Baddi facility
The United States Food and Drug Administration (US FDA) had conducted an inspection at the facility from July 15 to 19, 2019,"…
US FDA upgrades Jubilant’s Spokane facility to VAI status
It is indicative of the cGMP status at the facility since receiving the warning letter in 2013